Welcome to our dedicated page for Hologic news (Ticker: HOLX), a resource for investors and traders seeking the latest updates and insights on Hologic stock.
Hologic Inc (HOLX) delivers innovative healthcare solutions through diagnostic imaging systems and surgical technologies focused on women’s health. This dedicated news hub provides investors and industry professionals with essential updates directly from the company and verified sources.
Access timely Hologic press releases, earnings reports, and strategic announcements in one centralized location. Track developments across key business segments including diagnostic systems, breast health technologies, and minimally invasive surgical solutions. Our curated feed ensures you never miss regulatory filings, product approvals, or partnership announcements impacting this medical technology leader.
This resource serves as your primary source for monitoring Hologic’s advancements in healthcare diagnostics and operational milestones. Content is rigorously verified to maintain factual accuracy while avoiding speculative analysis. Bookmark this page for efficient tracking of HOLX’s progress in developing technologies that enhance clinical decision-making worldwide.
Hologic, Inc. (HOLX) reported its fiscal Q2 results, with revenues soaring 103.4% to $1.54 billion and EPS surging 561.1% to $2.38. This growth was fueled by a 390.6% increase in molecular diagnostics revenue, reaching $935.3 million, driven by strong demand for COVID-19 testing. The company completed acquisitions worth over $1 billion, aiming to enhance post-pandemic growth. Operating margin expanded to 51.8%, while cash flow from operations was $552.3 million. Despite strong results, future COVID testing revenue may be conservative, impacting Q3 guidance.
Hologic (HOLX) has entered into a definitive agreement to acquire Mobidiag Oy for an enterprise value of approximately $795 million. This transaction includes a cash payment of roughly $714 million and net debt of about $81 million. The acquisition aims to enhance Hologic's diagnostics business by expanding into acute care with Mobidiag's innovative molecular diagnostic tests, which target infections and antimicrobial resistance. Mobidiag generated around $42 million in revenue in 2020. The acquisition is expected to be slightly dilutive to Hologic's earnings in the first two years but accretive thereafter.
Hologic, Inc. (Nasdaq: HOLX) will announce its Q2 fiscal 2021 financial results on April 28 after market close. A conference call hosted by management will take place at 4:30 p.m. ET the same day. Interested listeners can join the call by dialing the provided numbers or by clicking a link. A replay will be available until May 21. Hologic focuses on enhancing women's health through early detection and treatment technologies.
Hologic, a leader in women's health, announced a collaboration with Gallup to create the Hologic Global Women’s Health Index, the most extensive assessment of women’s health globally. This survey will encompass over 120,000 responses across 116 countries and will track vital metrics related to women’s health, including reproductive health and access to care. The project aims to address healthcare disparities exacerbated by the COVID-19 pandemic and will provide insights for policy improvement. The index is set to be published later this year.
Hologic, Inc. (Nasdaq: HOLX) has acquired Diagenode, a European developer of molecular diagnostic assays, for approximately $159 million. This acquisition aims to enhance Hologic's molecular diagnostics capabilities, speeding up international market entry and expanding their test menu. Diagenode brings over 30 real-time PCR tests for various infections and significant expertise in epigenetics. The acquisition is expected to be break-even to Hologic's non-GAAP earnings per share through fiscal 2022, with potential for future accretion.
Hologic, Inc. (NASDAQ: HOLX) has successfully completed its acquisition of Biotheranostics, a leader in molecular oncology, for approximately $230 million. Biotheranostics specializes in molecular diagnostic tests such as the Breast Cancer Index and CancerTYPE ID, which aid in predicting treatment benefits and optimizing therapy for patients with uncertain cancers. Following the acquisition, Hologic aims to grow in the expanding oncology market, leveraging the National Comprehensive Cancer Network's recent endorsement of Breast Cancer Index as a key predictive tool for hormone-receptor positive breast cancer.
A recent study published in the Journal of the American College of Radiology highlights significant racial disparities in breast cancer screening, particularly in digital breast tomosynthesis (DBT). The research, commissioned by Hologic (HOLX), analyzed data from over 385,000 women across various racial backgrounds and found that Black women were less likely to receive DBT mammograms, despite their higher mortality rate from breast cancer. Hologic is dedicated to addressing these disparities through partnerships and initiatives aimed at increasing access to advanced screening technologies for Black women.
AMETEK announced the appointment of Karleen Oberton to its Board of Directors, effective February 11, 2021. Oberton currently serves as CFO of Hologic and has over 30 years of experience in public accounting, biotechnology, and medical device manufacturing. Her expertise in finance and executive leadership is expected to enhance AMETEK's board dynamics. The company reported 2020 sales exceeding $4.5 billion and aims for double-digit growth in earnings per share over the business cycle.
Hologic, Inc. (Nasdaq: HOLX) will present at several upcoming virtual investor conferences, highlighting its commitment to women's health technology. Key events include:
- BTIG Virtual MedTech Conference on February 17 at 10:30 a.m. ET
- Citi’s Healthcare Services Conference on February 24 at 11:40 a.m. ET
- SVB Leerink’s Global Healthcare Conference on February 25 at 1:00 p.m. ET
- Raymond James Institutional Investors Conference on March 1 at 1:20 p.m. ET
All presentations will be webcast live and accessible on Hologic's investor website.
FAQ
What is the current stock price of Hologic (HOLX)?
What is the market cap of Hologic (HOLX)?
